Curasight

The protocol amendment, announced in July 2026, is designed to optimize the delivery method and generate additional clinical information to support a robust dataset and inform subsequent therapeutic development. Under the amended protocol, newly enrolled patients will receive uTREAT® without mannitol-induced blood-brain barrier disruption.

Ulrich Krasilnikoff, CEO of Curasight, commented:

"We are very pleased that the amended protocol has now been approved and that patient enrolment can resume. The amendment reflects that we see the delivery method as an important feature of the program and underpins our data-driven approach. These data will help inform the subsequent dose-finding and phase 2 studies in the development of our glioblastoma program. We look forward to progressing enrolment and generating the additional data."

As announced in Curasight's Interim Report Q2 2026, topline data from the Phase 1 glioblastoma study are expected in H1 2027.